Destro 9x8 【2025-2027】

T-cell activation through "immunogenic cell death" to overcome traditional resistance to immunotherapy in MSS (microsatellite stable) colorectal cancer. 3.

CheckMate 9X8 is part of a broader field of study, alongside trials like AtezoTRIBE and MEDITREME, testing similar immunotherapeutic approaches. 4. Preliminary Findings & Objectives Destro 9x8

Based on the available search results, the "Destro 9x8" appears to refer to the , an ongoing clinical study in metastatic colorectal cancer (mCRC), often discussed in literature regarding immuno-oncology. Report: CheckMate 9X8 Trial Overview 1. Subject Subject Preliminary studies, such as the MEDITREME trial

Preliminary studies, such as the MEDITREME trial (a related study), showed promising early efficacy, with a six-month progression-free survival rate of 62.5%. Subject Preliminary studies

The study aims to enhance antitumor immune responses in treatment-naïve patients (those who have not previously received treatment) with mCRC.

The final results of the CheckMate 9X8 trial are expected to validate whether this immunotherapy combination provides a superior progression-free survival (PFS) or overall survival (OS) compared to standard chemotherapy alone.